SAN FRANCISCO--(BUSINESS WIRE)--Sequenta, Inc. today announced the publication in the journal BLOOD of two landmark studies involving more than 150 patients that demonstrate the company’s LymphoSIGHT™ next generation sequencing method is more sensitive than existing tools for detecting minimal residual disease (MRD). These studies provide clinical validation for the use of the LymphoSIGHT™ platform in the treatment of B cell acute lymphoblastic leukemia (ALL); the most common childhood cancer.
